Zargis Medical Corp. Begins Sale of Cardioscan Software, Addressing Cardiac Concerns
Source: http://Blog.QualityStocks.net/?p=17437Posted on Tuesday, August 25th, 2009 | In Market Commentary, Small & Micro Cap
Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE:SI), a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), develops diagnostic decision support products and services for healthcare professionals. The company today announced that it has begun selling its Zargis Cardioscan heart sound analysis software, as well as 3M Health Care’s (NYSE: MMM) recently launched Bluetooth-enabled 3M Littmann Electronic Stethoscope Model 3200.
The introduction of the products into the marketplace is part of Zargis’ existing multi-year global marketing deal with 3M, which equips Zargis with extended marketing and promotional opportunities, as well as worldwide distribution rights of its products through 3M’s Littmann brand.
Zargis’ Cardioscan software provides support to physicians, analyzing and interpreting cardiac sounds, which gives them an upper hand in dealing with possible heart disease. Cardioscan is wirelessly connected to 3M’s Littmann Electronic Stethoscope Model 3200, which allows users to easily share and compare heart sounds recordings and related comments over the Internet.
“The ability to record and automatically analyze heart sounds can help improve a clinician’s confidence, document complex auscultations, and may keep some patients from going through additional, unnecessary testing,” Joseph Tartaglia, MD, a practicing cardiologist in White Plains, NY, and clinical assistant professor of medicine at New York Medical College in Valhalla, NY, stated in the press release.
Today’s announcement comes in the middle of the U.S. healthcare controversy and the public call for improved and accessible healthcare.
“At a time when our nation is focused on leveraging technology to improve healthcare efficiency, these devices represents breakthroughs in auscultation that have the potential to reduce unnecessary referrals, and help clinicians detect pathologic heart murmurs earlier in the treatment cycle,” John Kallassy, CEO of Zargis stated. “We believe that the use of our software could enhance the physician experience during every patient exam where a stethoscope is used.”
Let us hear your thoughts below:
Last 5 posts by QualityStocks
- November 23rd CEOcast Weekly Newsletter - November 23rd, 2009
- Longwei Petroleum Investment Holdings Ltd. (LPHI) Reports Strong Third Quarter - November 23rd, 2009
- An Opportunity to Get there First in the Media Space - November 23rd, 2009
- Akeena Solar, Inc. (AKNS) Partners with Highland Solar Achieving Canadian Market Penetration - November 23rd, 2009
- Cardio Vascular Medical Device Corp. (CVSL.OB) Applying for Patents in Europe, Canada, and Far East - November 23rd, 2009
3m, 3M Health Care’s, bluetooth;, ceo, clinical assistant professor, diagnostic decision support, diagnostic decision support products, healthcare, healthcare efficiency, healthcare professionals, Heart Disease, heart sound analysis software, improved and accessible healthcare, John Kallassy, Joseph Tartaglia, Littmann, majority-owned subsidiary;, Market Commentary, New York, New York Medical College, physician, practicing cardiologist, Professor of Medicine, Siemens Corporate Research, Small & Micro Cap, Speedus Corp, U.S. Healthcare, Valhalla, White Plains, Zargis Cardioscan, Zargis Cardioscan heart sound analysis software, Zargis Medical Corp.
![]() About QualityStocks (http://QualityStocks.net)
Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. We believe strong management and vision for the future are crucial for any company to be successful. Timing is everything and we help investors succeed by providing an objective, broad-based view of the SmallCap markets on a daily basis. Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net |



